| | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
---|
|
L | | IP | | V/S | Fluarix Tetra 15 µg / 0.5 ml | | 9.58 | 26.85 | 10 % | | | GlaxoSmithKline AG | B / SL | FB | | G |  |
L | | IP | | V/S | Influvac Tetra 0.5 ml | | 9.58 | 26.85 | 10 % | | | Viatris Pharma GmbH | B / SL | FB | | G |  |
L | | IP | | V/S | VaxigripTetra | | 9.58 | 26.85 | 10 % | | | Sanofi-Aventis (Suisse) SA | B / SL | FB | | G |  |
| | IP | | V/S | Flucelvax Tetra | | 9.58 | 26.85 | 10 % | | Injection suspension: 3 Active Agents | Vifor (International) AG | B / SL | FB | | G |  |
L | | IP | | V/S | Efluelda 0.7 ml | | 31.00 | 48.80 | 10 % | | suspension injectable en seringue préremplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B / SL | FB | | G |  |
| | IP | | V/S | Fluarix Tetra 15 µg / 0.5 ml | 10 | PR | PR | k.A. | | | GlaxoSmithKline AG | B | FB | | G |  |
| | IP | | V/S | Influvac Tetra 0.5 ml | 10 | PR | PR | k.A. | | | Viatris Pharma GmbH | B | FB | | G |  |
| | IP | | V/S | VaxigripTetra | | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | VaxigripTetra | 10 | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | VaxigripTetra | 10 | PR | PR | k.A. | | | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Flucelvax Tetra | | PR | PR | k.A. | | Injection suspension: 3 Active Agents | Vifor (International) AG | B | FB | | G |  |
| | IP | | V/S | Flucelvax Tetra | 10 | PR | PR | k.A. | | Injection suspension: 3 Active Agents | Vifor (International) AG | B | FB | | G |  |
| | IP | | V/S | Flucelvax Tetra | 10 | PR | PR | k.A. | | Injection suspension: 3 Active Agents | Vifor (International) AG | B | FB | | G |  |
| | | | V/S | Efluelda TIV 0.5 mL | | PR | PR | k.A. | | suspension injectable en seringue pré-remplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | | | V/S | Efluelda TIV 0.5 mL | 10 | PR | PR | k.A. | | suspension injectable en seringue pré-remplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Efluelda 0.7 ml | | PR | PR | k.A. | | suspension injectable en seringue préremplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Efluelda 0.7 ml | 5 | PR | PR | k.A. | | suspension injectable en seringue préremplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Efluelda 0.7 ml | 5 | PR | PR | k.A. | | suspension injectable en seringue préremplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Efluelda 0.7 ml | 10 | PR | PR | k.A. | | suspension injectable en seringue préremplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Efluelda 0.7 ml | 10 | PR | PR | k.A. | | suspension injectable en seringue préremplie: 3 Active Agents | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |
| | IP | | V/S | Foclivia | | PR | PR | k.A. | | | Vifor (International) AG | B | FB | | G |  |
| | IP | | V/S | Foclivia | 10 | PR | PR | k.A. | | | Vifor (International) AG | B | FB | | G |  |
| | IP | | V/S | Foclivia | 10 | PR | PR | k.A. | | | Vifor (International) AG | B | FB | | G |  |
L | | IP | | V/S | Influvac | Fertigspritze(n) à 0.5 ml | 9.10 | 18.65 | k.A. | | Injection suspension: 3 Active Agents | Mylan Pharma GmbH | B / SL | FB | | G |  |
| | IP | | V/S | Influvac | Fertigspritze(n) à 0.5 ml | 9.10 | 18.65 | k.A. | | | Mylan Pharma GmbH | B | FB | | G |  |
| | IP | | V/S | Influvac | 10 1 Fertigspritze(n) à 0.5 ml | PR | PR | k.A. | | | Mylan Pharma GmbH | B | FB | | G |  |
| | IP | | V/S | Influvac | 10 1 Fertigspritze(n) à 0.5 ml | PR | PR | k.A. | | Injection suspension: 3 Active Agents | Mylan Pharma GmbH | B | FB | | G |  |
| | IP | | V/S | Optaflu | 0.5 ml | 10.05 | 19.70 | k.A. | | Vaccinum Influenzae Inactivatum ex Corticis Antigeniis Praeparatum (Cellulae Mdck) 2015/2016 | Novartis Pharma Schweiz AG | B | FB | | G |  |
| | IP | | V/S | Mutagrip | 0.5 ml | 8.51 | 17.95 | k.A. | | Vaccinum Influenzae-Split, Inactivatum 2018/2019 | Sanofi-Aventis (Suisse) SA | B | FB | | G |  |